Cardiology

Mechanism for pathogenesis of heart failure

A weak heart is unable to pump an adequate amount of blood around the body. In Germany, this condition is now the commonest reason for patients to be admitted to hospital. A research group from the Clinic for Internal Medicine III in the Faculty of Medicine at Kiel’s Christian Albrecht University (CAU) and Schleswig-Holstein University Hospital (Kiel Campus) has discovered a previously unknown heart muscle protein and also described a new mechanism by which heart failure can develop. The results of this work were published in the scientific journal Nature Communications.

Fluorescently labelled antibodies show the exact localisation of Myoscape...
Fluorescently labelled antibodies show the exact localisation of Myoscape protein (left image, green) and the calcium channel (centre image, red) in the heart muscle. Both are located at the same site in the cell membrane (right image, orange) where Myoscape binds to the calcium channel.
Source: Clinic for Internal Medicine III

Cardiovascular disease is one of the commonest causes of death in the Western world. It is triggered by a number of factors: circulatory disorders, inflammation or inherited conditions can all act to weaken the pumping action of the heart muscle. At the molecular level, one thing is common to all forms of heart failure: a disruption to the calcium metabolism of heart muscle cells. And this is the exact interaction site for the “Myoscape” protein newly discovered by Kiel cardiologists Dr Matthias Eden and Professor Norbert Frey.

Working together with researchers from Munich, Heidelberg and Paris, they were able to show that Myoscape binds to a specific calcium channel on the heart muscle and thus has a significant effect on its function. “In the absence of Myoscape, heart muscle cells in the model system develop a serious impairment of calcium channel metabolism, ultimately leading to progressive heart failure,” comments Frey. Conversely, the researchers were able to show that calcium channel currents increase significantly if levels of Myoscape protein in heart muscle cells are artificially increased. In such cases, the increased level of Myoscape is then even capable of restoring previously decreased calcium currents in failing heart muscle cells.

In further experiments, the researchers were ultimately able to elucidate the exact mechanism by which Myoscape influences calcium metabolism and the pumping ability of the heart muscle cell. “To function properly, the calcium channel needs to be located at the right position in the heart muscle cell,” Eden explains. This is because the binding of Myoscape and another protein called actinin 2 stabilises the calcium channel in the heart muscle cell at the correct position in the cell membrane. In the absence of Myoscape, the calcium channel is removed from the cell membrane and heart failure then develops. “Since patients with severe heart failure also exhibit reduced levels of Myoscape protein in the heart, we believe that we have here discovered a critical new mechanism for the genesis of heart failure,” says Frey. In the future, this could lead to the development of innovative forms of treatment.

The study was conducted and funded as a project by the German Centre for Cardiovascular Disease (DZHK). Kiel is just one of seven DZHK research sites throughout Germany, with others including Lübeck and Hamburg.

Source: Kiel’s Christian Albrecht University (CAU)

04.05.2016

Read all latest stories

Related articles

Photo

Cardiology research

Dynamic heart model gives insight into cardiac disease progression

Efforts to understand cardiac disease progression and develop therapeutic tissues that can repair the human heart are just a few areas of focus for the Feinberg research group at Carnegie Mellon…

Photo

Remote cardiology

A real-time telemonitoring device for heart failure patients

Medical monitoring tech company Umana Medical announced a collaboration with the Preventive Cardiology and Medical Prevention, Center of Cardiology at the University Medical Center Mainz and Bayer AG…

Photo

Cardiovascular disease prevention

An ultrasound sensor to measure pulse wave velocity and blood pressure

Nanoelectronics and digital technologies company Imec presents a proof-of-concept for determining arterial stiffness, a risk marker for cardiovascular diseases such as stroke and heart failure, and…

Related products

Alsachim, a Shimadzu group company – Dosinaco

Clinical Chemistry

Alsachim, a Shimadzu group company – Dosinaco

Alsachim, a Shimadzu Group Company
Lifotronic - FA-160 Immunofluorescence Analyzer

Other

Lifotronic - FA-160 Immunofluorescence Analyzer

Lifotronic Technology Co., Ltd
SIUI · Apogee 6500 Color Doppler Ultrasound Imaging System

Artificial Intelligence

SIUI · Apogee 6500 Color Doppler Ultrasound Imaging System

Shantou Institute of Ultrasonic Instruments Co., Ltd. (SIUI)
Ziehm – Vision R

Surgical II-C-Arms

Ziehm – Vision R

Ziehm Imaging GmbH
Subscribe to Newsletter